Chairman Yan (right) signs a contract with Vice Chairman Cui Wanchen
After five years of investigation, research, and negotiation both domestically and internationally, the "high-purity fish oil" project of Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (hereinafter referred to as Cheng Yi Pharmaceutical) with a content of 99% finally kicked off on December 10th, Chairman Yan Yiyi and Vice Chairman Cui Wanchen of Beijing Innovation Tongheng Technology Co., Ltd. held a signing ceremony at the Shanghai headquarters of Cheng Yi Pharmaceutical for the "Annual Production of 100 tons of High Purity Fish Oil EPA (API) Production Line Construction Project". This means that the first marine pharmaceutical product in China to treat cardiovascular diseases, the "High Purity Fish Oil" project, is about to break ground and start construction.
It is reported that after the listing of Cheng Yi Pharmaceutical, it actively developed a new generation of marine biopharmaceuticals with the main goal of treating cardiovascular diseases. After five years of arduous investigation and research, "high-purity fish oil" was finally selected as the development goal. The company collaborated with multiple high-tech enterprises and research institutions to jointly tackle key technologies and production equipment. Currently, Cheng Yi Pharmaceutical has selected high-purity fish oil as two major projects: fish oil soft capsules and raw materials. The fish oil soft capsule workshop is located in the newly built formulation building; At the same time, 106 acres of new land will be requisitioned next to the first phase of the "Health Industry Park", and the "High Purity Fish Oil EPA Production Line (API)" will be constructed quickly.
According to experts, the single component pharmaceutical grade EPA with an ultra-high purity content of 99% extracted using simulated moving bed technology is known as the "vascular scavenger". This technology was approved by the US FDA in 2019, but it is still blank in China. According to research, it can effectively regulate blood lipids, reduce blood viscosity, and prevent thrombosis; It can also reduce blood pressure, prevent fat deposition in the vascular wall, prevent the formation and development of atherosclerosis, and prevent cardiovascular diseases such as cerebral thrombosis, cerebral hemorrhage and hypertension.
Cheng Yi Pharmaceutical is the earliest pharmaceutical enterprise in China to involve the use of super chromatography technology to produce high-purity fish oil EPA. It has strong cost and quality advantages in basic raw materials, key manufacturing equipment, GMP management, and a good foundation for long-term raw material drug production.
It is reported that the production equipment for "fish oil soft capsules" will start installation later this month, and it is expected to undergo validation batch trial production in March 2021; The "High Purity Fish Oil EPA Production Line" is expected to undergo trial production in June 2021. The company will submit a drug registration application to the National Drug Administration and the US FDA as soon as possible. After approval, it will provide high-quality and high-purity EPA raw materials and formulation products to the domestic and foreign pharmaceutical markets.
Chairman Yan (right) and Vice Chairman Cui Wanchen exchanged greetings after signing the contract
On December 10th, Ren Bingjun, Vice Chairman of Cheng Yi Pharmaceutical, Zhao Chunjian, General Manager of the company, and Cui Wanjiang, Chairman of Beijing Innovation Tongheng Technology Co., Ltd. attended the signing ceremony.
Article source: Dazhong Securities News